ATM and neoplasm: Thus, the mutational status of genes such as ATM may be one of several factors that, in the setting of a multidisciplinary BrM tumor board, could guide whether to approach a BrM with primary SRS, with surgery, or to reimage the brain following a trial of systemic therapy.